Federal Register / Vol. 62, No. 191 / Thursday, October 2, 1997 / Notices 51671

Licensing Contact: J. Peter Kim, 301/

496–7056 ext. 264

The invention provides compositions

and methods directed to isolated α

subunits of the 7TM protein CD97.

CD97 is a heterodimer existing in three

isoforms, namely three forms of α

subunit and one invariant β subunit.

The invention provides compositions

and methods for detecting a subunit of

CD97, a T-cell protein which is

unregulated in activated T-cells and is

involved in the onset and maintenance

of inflammation and angiogenesis. The

invention provides an isolated protein

comprising a soluble CD97 α subunit,

and an isolated nucleic acid encoding a

soluble Cd97 α subunit protein. The

invention also provides methods for

identifying compounds which inhibit

soluble CD97 α subunit expression. The

invention may be used to inhibit

angiogenesis associated with chronic

inflammation in a mammal by

administering a therapeutically effective

amount of a CD97 antagonist. Another

application includes determining the

degree of inflammation at a site in a

mammal with an antibody composition

specifically reactive to a soluble CD97 α

subunit. Further, it should be noted that

these compositions and methods further

have in vitro utility in the construction

of proteins and subsequences thereof for

the construction of antibodies, and

nucleic acids and subsequences thereof

for use as probes.

Peptides With Laminin Activity

Y Yamada, JO Graf, Y Iwamoto, F

Robey, HK Kleinman,

M Sasaki, GR Martin (NIDR)

U.S. Patent 5,092,885 issued 03 Mar 92

Licensing Contact: Jaconda Wagner,

301/496–7735, ext. 284

Peptides with laminin activity,

including YIGSR, are claimed. These

peptides block angiogenesis, alter the

formation of capillary structures by

endothelial cells, prevent the formation

of excess blood vessels in tissue and

inhibit in vivo tumor cell colonization

of tissues. These peptides can be used,

among other things, to inhibit

metastasis.

This research has been described in

B.J. Cancer 73:589, 1996; Cancer Res

54:5005, 1994; Semin Cancer Biol 1993

Aug; 4(4):259–65; Cancer Res 1993 Aug

1;53(15):3459–61; Cell 1987 Mar

27;48(6):989–9.

Laminin A Peptides

Y Yamada, HK Kleiman, M Sasaki, GR

Martin (NIDR)

U.S. Patent 5,211,657 issued 18 May 93

Licensing Contact: Jaconda Wagner,

301/496–7735, ext. 284

This invention relates to peptides and

derivatives thereof having laminin-like

activity, as well as a pharmaceutical

composition of the peptide. The

peptides claimed include SerineIsoleucine-Lysine-Valine-AlanineValine (SIKVAV). Methods for

promoting increased adhesion and

migration of epithelial cells is also

disclosed. The peptides have wide

usage in research, nerve regeneration

and cancer treatment. For example, this

invention may be useful as an adhesion

and regeneration agent for nerve guides

and as an adhesion agent for vascular

prothesis.

This research had been described in

Bioorganic Medinal Chem Lett 5:711,

1995; J Neurosci Res 1995 Oct

15;42(3):314–22; Cancer Res 1995 Jun

1;55(11):2476–80; FEBS Lett 1995 May

29;365(2–3):227–3; J Cell Physiol 1994

Jul;160(1):185–93; Cell Immunol 1994

Jan; 153(1):94–104.

Dated: September 25, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–26171 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Efficacy Studies of

Chemopreventive Agents in animal Models

and Evaluation of Chemopreventive Agents

by in Vivo Screening Assays.

Date: October 20–21, 1997.

Time: 8:30 a.m. to 5:00 p.m.

Place: Double Tree Hotel—Rockville, 1750

Rockville Pike, Rockville, MD 20852.

Contact Person: Courtney M. Kerwin,

Ph.D., M.P.H., Scientific Review

Administrator, National Cancer Institute,

NIH, Executive Plaza North, Room 630I, 6130

Executive Boulevard, MSC 7405, Bethesda,

MD 20892–7405, Telephone: 301/496–7421.

Purpose/Agenda To review and evaluate

proposals submitted in response to master

agreement announcements.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Proposals and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control.)

Dated: September 26, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–26167 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 United States Code

Appendix 2), notice is hereby given of

the following National Institute of Child

Health and Human Development

Special Emphasis Panel (SEP) meeting:

Name of SEP: Duration of Labor and

Cesarean Delivery in Association With

Epidural Analgesia in Nullipara

(Teleconference).

Date: September 30, 1997.

Time: 11:00 a.m. (ET)—adjournment.

Place: 6100 Executive Boulevard, 6100

Building—Room 5E01, Rockville, Maryland

20852.

Contact Person: Hameed Khan, Ph.D.,

Scientific Review Administrator, NICHD,

6100 Executive Boulevard, 6100 Building—

Room 5E01, Rockville, Maryland 20852,

Telephone: 301–496–1696.

Purpose/Agenda: To provide concept

review of proposed contract solicitations.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(9)(B), Title 5 U.S.C. The discussions

could reveal the specific details of future

requests for contract proposals (RFPs), the

disclosure of which would significantly

frustrate implementation of the agency’s

proposed contract activities by giving unfair

competitive advantage to private firms or

individuals.

This notice is published less than 15 days

prior to the meeting due to the urgent need

to meet timing limitations imposed by the

review and funding cycle.

(Catalog of Federal Domestic Assistance

Program Nos. [93.864, Population Research

and No. 93.865, Research Mothers and

Children], National Institutes of Health)

Dated: September 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–26099 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M